286 related articles for article (PubMed ID: 15758787)
21. Treatment for substance use disorders in a privately insured population under managed care: costs and services use.
Greenfield SF; Azzone V; Huskamp H; Cuffel B; Croghan T; Goldman W; Frank RG
J Subst Abuse Treat; 2004 Dec; 27(4):265-75. PubMed ID: 15610828
[TBL] [Abstract][Full Text] [Related]
22. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work.
Li X; Gignac MA; Anis AH
Med Care; 2006 Apr; 44(4):304-10. PubMed ID: 16565630
[TBL] [Abstract][Full Text] [Related]
23. The economic burden of smoking in California.
Max W; Rice DP; Sung HY; Zhang X; Miller L
Tob Control; 2004 Sep; 13(3):264-7. PubMed ID: 15333882
[TBL] [Abstract][Full Text] [Related]
24. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates.
Yelin E; Cisternas MG; Pasta DJ; Trupin L; Murphy L; Helmick CG
Arthritis Rheum; 2004 Jul; 50(7):2317-26. PubMed ID: 15248233
[TBL] [Abstract][Full Text] [Related]
25. The costs of cancer to a major employer in the United States: a case-control analysis.
Barnett A; Birnbaum H; Cremieux PY; Fendrick AM; Slavin M
Am J Manag Care; 2000 Nov; 6(11):1243-51. PubMed ID: 11185849
[TBL] [Abstract][Full Text] [Related]
26. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.
Owusu-Edusei K; Tejani MN; Gift TL; Kent CK; Tao G
Sex Transm Dis; 2009 Jun; 36(6):395-9. PubMed ID: 19556934
[TBL] [Abstract][Full Text] [Related]
27. Direct cost burden among insured US employees with migraine.
Hawkins K; Wang S; Rupnow M
Headache; 2008 Apr; 48(4):553-63. PubMed ID: 18070057
[TBL] [Abstract][Full Text] [Related]
28. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States.
Brook RA; Wahlqvist P; Kleinman NL; Wallander MA; Campbell SM; Smeeding JE
Aliment Pharmacol Ther; 2007 Sep; 26(6):889-98. PubMed ID: 17767473
[TBL] [Abstract][Full Text] [Related]
29. Urologic diseases in America project: urinary incontinence in males--demographics and economic burden.
Stothers L; Thom D; Calhoun E
J Urol; 2005 Apr; 173(4):1302-8. PubMed ID: 15758786
[TBL] [Abstract][Full Text] [Related]
30. Burden of venous leg ulcers in the United States.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
[TBL] [Abstract][Full Text] [Related]
31. Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
Robinson RL; Birnbaum HG; Morley MA; Sisitsky T; Greenberg PE; Claxton AJ
J Rheumatol; 2003 Jun; 30(6):1318-25. PubMed ID: 12784409
[TBL] [Abstract][Full Text] [Related]
32. [Socioeconomic costs of stroke in Korea: estimated from the Korea national health insurance claims database].
Lim SJ; Kim HJ; Nam CM; Chang HS; Jang YH; Kim S; Kang HY
J Prev Med Public Health; 2009 Jul; 42(4):251-60. PubMed ID: 19675402
[TBL] [Abstract][Full Text] [Related]
33. Economic burden of epilepsy among the privately insured in the US.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Pharmacoeconomics; 2010; 28(8):675-85. PubMed ID: 20623993
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
35. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
36. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?
Saigal CS; Joyce G; Timilsina AR;
Kidney Int; 2005 Oct; 68(4):1808-14. PubMed ID: 16164658
[TBL] [Abstract][Full Text] [Related]
37. Indirect cost of ischemic heart disease to employers.
Guico-Pabia CJ; Murray JF; Teutsch SM; Wertheimer AI; Berger ML
Am J Manag Care; 2001 Jan; 7(1):27-34. PubMed ID: 11209448
[TBL] [Abstract][Full Text] [Related]
38. Annual costs of benign prostatic hyperplasia in New Zealand.
Scott WG; Scott HM
Pharmacoeconomics; 1993 Dec; 4(6):455-68. PubMed ID: 10151048
[TBL] [Abstract][Full Text] [Related]
39. Economic cost of Guillain-Barré syndrome in the United States.
Frenzen PD
Neurology; 2008 Jul; 71(1):21-7. PubMed ID: 18591502
[TBL] [Abstract][Full Text] [Related]
40. Impact of a musculoskeletal disability management program on medical costs and productivity in a large manufacturing company.
Bunn WB; Baver RS; Ehni TK; Stowers AD; Taylor DD; Holloway AM; Duong D; Pikelny DB; Sotolongo D
Am J Manag Care; 2006 Dec; 12 Spec no.():SP27-32. PubMed ID: 17173488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
